FDA's CFS/ME Drug Development Workshop: Day Two: Afternoon Panels ProHealth In his discussion of the rituximab study, Dr. Rowe pointed out that results need to be measured within the context of specific outcomes: cognitive improvement, activity, and functional measures. Simply asking patients how they feel compared with how ... |
